All lobbying filings
FORBES-TATE
FORBES-TATE filed a Q3 report for HALOZYME THERAPEUTICS, INC. on October 18, 2026, reporting $80,000 in lobbying income.
Lobbying for HALOZYME THERAPEUTICS, INC. · U.S. Biotechnology Company
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 18, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
California
Government bodies contacted
4
Lobbying activity
2
Issues related to biopharmaceutical research, development, and manufacturing.
Issues related to coverage and reimbursement.